CN113666931A - Preparation method of high-purity calcium levofolinate - Google Patents
Preparation method of high-purity calcium levofolinate Download PDFInfo
- Publication number
- CN113666931A CN113666931A CN202111042834.5A CN202111042834A CN113666931A CN 113666931 A CN113666931 A CN 113666931A CN 202111042834 A CN202111042834 A CN 202111042834A CN 113666931 A CN113666931 A CN 113666931A
- Authority
- CN
- China
- Prior art keywords
- calcium
- solid
- levofolinate
- filtering
- calcium levofolinate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960001921 calcium levofolinate Drugs 0.000 title claims abstract description 82
- KVUAALJSMIVURS-QNTKWALQSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioate Chemical compound [Ca+2].C([C@@H]1N(C=O)C=2C(=O)N=C(NC=2NC1)N)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-QNTKWALQSA-L 0.000 title claims abstract description 79
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000007787 solid Substances 0.000 claims abstract description 123
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 54
- 239000000047 product Substances 0.000 claims abstract description 52
- 238000001914 filtration Methods 0.000 claims abstract description 51
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 claims abstract description 39
- 239000011687 calcium folinate Substances 0.000 claims abstract description 39
- 235000008207 calcium folinate Nutrition 0.000 claims abstract description 38
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 22
- 239000000706 filtrate Substances 0.000 claims abstract description 22
- 238000001035 drying Methods 0.000 claims abstract description 15
- 239000012043 crude product Substances 0.000 claims abstract description 14
- 238000003756 stirring Methods 0.000 claims abstract description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 48
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 150000007524 organic acids Chemical class 0.000 claims description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 12
- 239000011575 calcium Substances 0.000 claims description 12
- 229910052791 calcium Inorganic materials 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 235000019152 folic acid Nutrition 0.000 claims description 10
- 239000011724 folic acid Substances 0.000 claims description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 9
- 229960000304 folic acid Drugs 0.000 claims description 9
- 238000002425 crystallisation Methods 0.000 claims description 7
- 230000008025 crystallization Effects 0.000 claims description 7
- 230000001376 precipitating effect Effects 0.000 claims description 6
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 claims description 5
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 230000022244 formylation Effects 0.000 claims description 3
- 238000006170 formylation reaction Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 2
- 238000007670 refining Methods 0.000 claims description 2
- 239000012535 impurity Substances 0.000 abstract description 43
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract description 16
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 abstract description 16
- 239000001639 calcium acetate Substances 0.000 abstract description 16
- 235000011092 calcium acetate Nutrition 0.000 abstract description 16
- 229960005147 calcium acetate Drugs 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract description 3
- 229910001424 calcium ion Inorganic materials 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 239000013064 chemical raw material Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 238000010586 diagram Methods 0.000 description 32
- 238000005406 washing Methods 0.000 description 30
- 230000000052 comparative effect Effects 0.000 description 28
- 238000001816 cooling Methods 0.000 description 24
- 238000010438 heat treatment Methods 0.000 description 24
- 235000011054 acetic acid Nutrition 0.000 description 15
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 12
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 239000002994 raw material Substances 0.000 description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 7
- 239000001110 calcium chloride Substances 0.000 description 7
- 229910001628 calcium chloride Inorganic materials 0.000 description 7
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 description 6
- 229940075961 levoleucovorin calcium pentahydrate Drugs 0.000 description 6
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- CBOCVOKPQGJKKJ-UHFFFAOYSA-L Calcium formate Chemical compound [Ca+2].[O-]C=O.[O-]C=O CBOCVOKPQGJKKJ-UHFFFAOYSA-L 0.000 description 5
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 5
- 235000019255 calcium formate Nutrition 0.000 description 5
- 239000004281 calcium formate Substances 0.000 description 5
- 229940044172 calcium formate Drugs 0.000 description 5
- 235000010331 calcium propionate Nutrition 0.000 description 5
- 239000004330 calcium propionate Substances 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 238000006317 isomerization reaction Methods 0.000 description 5
- 235000019260 propionic acid Nutrition 0.000 description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 5
- HNXQXTQTPAJEJL-UHFFFAOYSA-N 2-aminopteridin-4-ol Chemical compound C1=CN=C2NC(N)=NC(=O)C2=N1 HNXQXTQTPAJEJL-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 2
- GADGMZDHLQLZRI-VIFPVBQESA-N N-(4-aminobenzoyl)-L-glutamic acid Chemical compound NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 GADGMZDHLQLZRI-VIFPVBQESA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 159000000007 calcium salts Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- -1 organic acid calcium salt Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention belongs to the field of synthesis of chemical raw material medicines, and particularly relates to a preparation method of high-purity calcium levofolinate, which comprises the following steps: s-1, adding calcium folinate and a resolving agent into water, stirring to dissolve the calcium folinate and the resolving agent, and filtering to obtain a filtrate; s-2, adding calcium acetate and a resolving agent into the filtrate, crystallizing and filtering to obtain a primary resolved solid; s-3, dissolving, crystallizing, filtering and drying the primary split solid to obtain a crude calcium levofolinate product; s-4, purifying the crude product of the calcium levofolinate to obtain a finished product of the calcium levofolinate; the resolving agent is R- (alpha) -phenylethylamine. The invention introduces calcium ions in the form of calcium acetate, avoids the introduction of chloride ions, and has no chloride ion impurities in the finished product. In addition, R- (alpha) -phenylethylamine is used as a resolving agent and is matched with calcium acetate, so that the isomer of a finished product is less than 0.1% (less than 0.5% specified in pharmacopoeia).
Description
Technical Field
The invention belongs to the field of synthesis of chemical raw material medicines, and particularly relates to a preparation method of high-purity calcium levofolinate.
Background
Calcium levofolinate is calcium salt of levofolinic acid, and levofolinic acid is L-optical isomer with pharmacological activity of 5-formyltetrahydrofolic acid (i.e. folinic acid). The levofolinic acid can participate in a reaction using folate as a source of one-carbon units without being reduced by dihydrofolate reductase, and the levofolinic acid can actively or passively pass through cell membranes. The basic action of levofolinic acid is the same as that of folic acid, but the effect is better than that of folic acid, which is changed into folinic acid in liver and bone marrow to play a role. The product, calcium levofolinate, is the active form of levofolinate, and also has the effect of stimulating the growth and maturation of leucocytes, and can improve megaloblastic anemia.
In addition, calcium levofolinate has also been used in combination with methotrexate or fluorouracil in practice to treat other types of malignancies, often as a member of a multi-drug combination regimen.
The levofolinic acid calcium is an active optical rotation body of the folinic acid calcium and has comparative advantages in the aspects of drug effect and safety. The product will gradually replace calcium folinate to become a new army in the domestic antitumor drug market in the future. Has wide market prospect in developing calcium levofolinate products.
Regarding the preparation of calcium levofolinate, for example, patent No. CN103113372A discloses a high-yield preparation method of calcium levofolinate, which prepares calcium levofolinate by a splitting process, wherein a solution containing calcium levofolinate is added during the splitting process, and calcium levofolinate in the calcium levofolinate solution accounts for more than 70% of the total amount of calcium folinate. However, at present, the purity of the levorotatory calcium folinate is difficult to meet the requirement, and the price of the levorotatory calcium folinate is several times that of the calcium folinate; the purity of the raw material medicine directly influences the safety of the medicine, and the price of the medicine is directly related to the production cost and the income of the medicine, so that whether the medicine can be safely used in a large range or not is determined. And most of the preparation processes introduce chloride ions, so that the content of the chloride ions in the product can not meet the standard.
Disclosure of Invention
The invention provides a preparation method of high-purity calcium levofolinate, which is free from introducing chloride ions and has optical purity of 99.95 percent.
The invention adopts the following technical scheme:
a preparation method of high-purity calcium levofolinate comprises the following steps:
s-1, adding calcium folinate and a resolving agent into water, stirring to dissolve the calcium folinate and the resolving agent, and filtering to obtain a filtrate;
s-2, adding organic acid calcium and a resolving agent into the filtrate, crystallizing and filtering to obtain a primary resolved solid;
s-3, filtering and drying the primary split solid to obtain a crude calcium levofolinate product;
and S-4, refining the crude product of the calcium levofolinate to obtain a finished product of the calcium levofolinate.
The resolving agent is R- (alpha) -phenylethylamine.
In the technical scheme, calcium ions are introduced in the form of organic acid calcium, so that the introduction of chloride ions is avoided, and the finished product is free of chloride ion impurities. In addition, R- (alpha) -phenylethylamine is used as a resolving agent and is matched with organic acid calcium, so that the isomer of a finished product is less than 0.1% (less than 0.5% specified in pharmacopoeia). The organic acid calcium salt can be calcium formate, calcium acetate, calcium propionate, etc.
The calcium chloride is replaced by the organic acid calcium, so that not only is the chlorine pollution of finished products caused by the introduction of chloride ions avoided, but also the splitting system is more stable, the impurities are reduced, and the optical purity of the obtained calcium levofolinate finished products can reach 99.95% by combining with an R- (alpha) -phenylethylamine splitting agent.
Preferably, after the primary resolved solid is obtained, dropwise adding acid into the primary resolved solid, then adding organic acid calcium and a resolving agent, crystallizing and filtering to obtain a secondary resolved solid; and filtering and drying the secondary split solid to obtain a crude calcium levofolinate product.
Preferably, in step S-5, the purification method of the crude calcium levofolinate comprises the following steps:
s-11, adding the crude calcium levofolinate into purified water, and adjusting the pH value with acetic acid to obtain a dissolved solution;
s-12, filtering the dissolved solution, adding absolute ethyl alcohol into the filtrate, filtering, precipitating and drying to obtain the finished calcium levofolinate.
Preferably, the calcium folinate is prepared from NaHSO3 Reducing folic acid to tetrahydrofolic acid, and preparing calcium folinate by using ethyl formate as a formylation reagent.
With conventional boron hydrogenSodium hydride or catalytic hydrogenation reduction method, the reduction is incomplete, a large amount of dihydrofolic acid is generated, or the reactant is subjected to molecular breakage, a byproduct is generated, the yield is reduced, and the separation and purification are difficult. With NaHSO3As a reducing agent, TLC was examined for the presence of no pterin, p-aminobenzoylglutamic acid and other impurity spots due to molecular cleavage. And with NaHSO in comparison with other reducing agents3The reduced folic acid has the advantages of lower cost, simpler operation, high yield and the like.
Preferably, the acid used in step S-3 is a low-carbon fatty acid such as formic acid, acetic acid, propionic acid, etc., instead of the conventionally used hydrochloric acid, so as to avoid chlorine pollution of the finished product due to the introduction of chloride ions.
Preferably, in steps S-2 and S-3, the crystallization temperature is 0 to 20 ℃ and the crystallization time is 5 to 10 hours, more preferably 5 to 6 hours.
Through implementing the technical scheme, compared with the prior art, the invention has the following improvement points and advantages:
1. calcium ions are introduced in the form of organic acid calcium (calcium formate, calcium acetate, calcium propionate), and organic acid (formic acid, acetic acid, propionic acid and the like) is used for replacing hydrochloric acid to adjust the pH value, so that the introduction of chloride ions is avoided, and the finished product has no chloride ion impurities.
2. R- (alpha) -phenylethylamine is used as a resolving agent and is matched with organic acid calcium, so that the isomer of a finished product is less than 0.1% (less than 0.5% specified in pharmacopoeia).
3. The calcium chloride is replaced by the organic acid calcium, so that not only is the chlorine pollution of finished products caused by the introduction of chloride ions avoided, but also the splitting system is more stable, the impurities are reduced, and the optical purity of the obtained calcium levofolinate finished products can reach 99.95% by combining with an R- (alpha) -phenylethylamine splitting agent.
4. The adoption of organic acid calcium (especially calcium acetate) and R- (alpha) -phenylethylamine has been found to greatly shorten the crystallization time, and compared with 20 hours in the prior art, the invention can complete the crystallization within 5 hours.
5. With NaHSO3 Reducing folic acid to tetrahydrofolic acid, preparing calcium folinate with ethyl formate as formylating agent, and preparing the productThe occurrence of pterin, p-aminobenzoylglutamic acid and other impurity spots generated by molecular cleavage was found. And with NaHSO in comparison with other reducing agents3The reduced folic acid has the advantages of lower cost, simpler operation, high yield and the like.
Drawings
FIG. 1 is an isomeric diagram of the primary resolved solid obtained in example 1;
FIG. 2 is an impurity profile of the primary resolved solid obtained in example 1;
FIG. 3 is an isomeric diagram of the twice-resolved solid obtained in example 1;
FIG. 4 is an impurity profile of the twice-resolved solid obtained in example 1;
FIG. 5 is an isomeric diagram of the crude calcium levofolinate obtained in example 1;
FIG. 6 is an impurity profile of the crude calcium levofolinate obtained in example 1;
FIG. 7 is the isomeric diagram of the calcium levofolinate product obtained in example 1;
FIG. 8 is an impurity profile of the calcium levofolinate product obtained in example 1;
FIG. 9 is an isomeric diagram of the primary resolved solid obtained in comparative example 1;
FIG. 10 is an impurity profile of the primary resolved solid obtained in comparative example 1;
FIG. 11 is an isomerization diagram of the twice-resolved solid obtained in comparative example 1;
FIG. 12 is an impurity map of the twice-resolved solid obtained in comparative example 1;
FIG. 13 is an isomeric diagram of the crude calcium levofolinate obtained in comparative example 1;
FIG. 14 is an impurity profile of the crude calcium levofolinate obtained in comparative example 1;
FIG. 15 is an isomeric diagram of the calcium levofolinate product obtained in comparative example 1;
FIG. 16 is an impurity profile of the calcium levofolinate product obtained in comparative example 1;
FIG. 17 is an isomerization diagram of the primary resolved solid obtained in comparative example 2;
FIG. 18 is an impurity profile of the primary resolved solid obtained in comparative example 2;
FIG. 19 is an isomerization diagram of the twice-resolved solid obtained in comparative example 2;
FIG. 20 is an impurity map of the twice-resolved solid obtained in comparative example 2;
FIG. 21 is an isomeric diagram of the crude calcium levofolinate obtained in comparative example 2;
FIG. 22 is an impurity profile of the crude calcium levofolinate obtained in comparative example 2;
FIG. 23 is an isomeric diagram of the calcium levofolinate product obtained in comparative example 2;
FIG. 24 is an impurity profile of the calcium levofolinate product obtained in comparative example 2;
FIG. 25 is an isomerization diagram of the primary resolved solid obtained in comparative example 3;
FIG. 26 is an impurity profile of the primary resolved solid obtained in comparative example 3;
FIG. 27 is an isomerization diagram of the twice-resolved solid obtained in comparative example 3;
FIG. 28 is an impurity map of the twice-resolved solid obtained in comparative example 3;
FIG. 29 is an isomeric diagram of the crude calcium levofolinate obtained in comparative example 3;
FIG. 30 is an impurity profile of the crude calcium levofolinate obtained in comparative example 3;
FIG. 31 is an isomeric diagram of the calcium levofolinate product obtained in comparative example 3;
FIG. 32 is an impurity profile of the calcium levofolinate product obtained in comparative example 3;
FIG. 33 is an isomeric diagram of the calcium levofolinate product obtained in example 2;
FIG. 34 is an impurity profile of the calcium levofolinate product obtained in example 2;
FIG. 35 is an isomeric diagram of the calcium levofolinate product obtained in example 3;
FIG. 36 is an impurity profile of the calcium levofolinate product obtained in example 3.
Detailed Description
The invention is further illustrated by the following specific examples.
It should be noted that the following embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; although the present invention has been described in detail with reference to the following embodiments, those skilled in the art will understand that: the technical scheme described in each embodiment can still be modified, or equivalent replacement can be carried out on part of technical features; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Example 1
The high-purity levorotatory calcium folinate is prepared by taking calcium folinate as a raw material, and comprises the following steps:
suspending 51.1g (0.1 m o l) calcium folinate and 25g sodium bromide in 400ml water, heating to 50 ℃ to dissolve, cooling the dissolved solution to 10 ℃ to crystallize for 6h, separating out solid, filtering, washing the solid with water, and combining the filtrates.
Adding 10g of calcium acetate and 2g R- (alpha) -phenylethylamine into the filtrate, cooling the solution to 10 ℃, crystallizing for 6h, separating out a solid, filtering, and washing the solid with water to obtain 59g of a primary resolution solid, wherein the yield is =90%, the primary resolution isomeric pattern is shown in figure 1, and the primary resolution impurity pattern is shown in figure 2.
Suspending the total amount of the first resolved solid in 400ml water, heating to 50 deg.C, adding acetic acid to dissolve, adding 10g calcium acetate and 2g R- (alpha) -phenylethylamine into the dissolved solution, cooling to 10 deg.C, crystallizing for 6 hr, separating out solid, filtering, and washing with water to obtain 51g second resolved solid,The yield is =90%, the secondary resolution isomerism spectrum is shown in figure 3, and the secondary resolution impurity spectrum is shown in figure 4.
Suspending the total amount of the secondary split solid in 400ml of water, heating to 50 ℃, adding acetic acid to dissolve the secondary split solid, adding 10g of calcium acetate and 2g R- (alpha) -phenylethylamine into the dissolved solution, cooling the dissolved solution to 10 ℃, crystallizing for 6h, separating out the solid, filtering, and washing the solid with water to obtain 44.5g of tertiary split solid-calcium levofolinate crude product, wherein the yield is =90%, the crude product isomeric diagram is shown in figure 5, and the crude product impurity diagram is shown in figure 6.
Suspending the crude calcium levofolinate in 400ml of water, heating to 50 ℃, adding acetic acid to dissolve the crude calcium levofolinate, adding 1500ml of absolute ethyl alcohol into the dissolved solution to crystallize for 5 hours, separating out solids, filtering, washing with absolute ethyl alcohol, and drying to obtain 13.5g of a finished calcium levofolinate product, wherein the yield is =92%, the chloride is less than or equal to 0.05%, the isomeric pattern of the finished product is shown in figure 7, and the impurity pattern of the finished product is shown in figure 8.
Comparative example 1:
the high-purity levorotatory calcium folinate is prepared by taking a crude calcium folinate product as a raw material, and comprises the following steps:
suspending 51.1g (0.1 m o l) crude calcium folinate and 25g sodium bromide in 400ml water, heating to 50 ℃ to dissolve, cooling the dissolved solution to 15 ℃ to crystallize for 6h, separating out solid, filtering, washing the solid with water, and combining the filtrates.
Adding 10g of calcium chloride and 2g R- (alpha) -phenylethylamine into the filtrate, cooling the dissolved solution to 15 ℃, crystallizing for 6h, separating out a solid, filtering, and washing the solid with water to obtain 57g of a primary resolution solid, wherein the yield is =88%, the primary resolution isomeric pattern is shown in figure 9, and the primary resolution impurity pattern is shown in figure 10.
Suspending the total amount of the first-resolution solid in 400ml of water, heating to 50 ℃, adding acetic acid to dissolve the first-resolution solid, adding 10g of calcium chloride and 2g R- (alpha) -phenylethylamine into the dissolved solution, cooling the dissolved solution to 15 ℃, crystallizing for 6h, separating out the solid, filtering, and washing the solid with water to obtain 49g of second-resolution solid, wherein the yield is =87%, the second-resolution isomeric pattern is shown in figure 11, and the second-resolution impurity pattern is shown in figure 12.
Suspending the total amount of the secondary split solid in 400ml of water, heating to 50 ℃, adding acetic acid to dissolve the secondary split solid, adding 10g of calcium chloride and 2g R- (alpha) -phenylethylamine into the dissolved solution, cooling the dissolved solution to 15 ℃, crystallizing for 6h, separating out the solid, filtering, and washing the solid with water to obtain 41g of the tertiary split solid-calcium levofolinate crude product, wherein the yield is =90%, the crude product isomeric diagram is shown in figure 13, and the crude product impurity diagram is shown in figure 14.
Suspending the crude calcium levofolinate in 400ml of water, heating to 50 ℃, adding acetic acid to dissolve the crude calcium levofolinate, adding 1500ml of absolute ethyl alcohol into the dissolved solution to crystallize for 5 hours, separating out solids, filtering, washing with absolute ethyl alcohol, and drying to obtain 12.5g of a finished calcium levofolinate product, wherein the yield is =92%, the chloride is not less than 0.5%, the isomeric pattern of the finished product is shown in figure 15, and the impurity pattern of the finished product is shown in figure 16.
The difference from example 1 is that calcium acetate is replaced by calcium chloride.
Comparative example 2:
the high-purity levorotatory calcium folinate is prepared by taking a crude calcium folinate product as a raw material, and comprises the following steps:
suspending 51.1g (0.1 m o l) crude calcium folinate and 25g sodium bromide in 400ml water, heating to 50 ℃ to dissolve, cooling the dissolved solution to 15 ℃ to crystallize for 6h, separating out solid, filtering, washing the solid with water, and combining the filtrates.
Adding 10g of calcium acetate and 2g S-methylbenzylamine into the filtrate, cooling the solution to 15 ℃, crystallizing for 6h, separating out a solid, filtering, and washing the solid with water to obtain 52.5g of a primary resolved solid, wherein the yield is =80%, the primary resolved isomeric pattern is shown in figure 17, and the primary resolved impurity pattern is shown in figure 18.
Suspending the total amount of the first-resolution solid in 400ml of water, heating to 50 ℃, adding acetic acid to dissolve the first-resolution solid, adding 10g of calcium acetate and 2g S-methylbenzylamine into the dissolved solution, cooling the dissolved solution to 15 ℃, crystallizing for 6h, separating out the solid, filtering, and washing the solid with water to obtain 47g of second-resolution solid, wherein the yield is =86%, the second-resolution isomeric pattern is shown in figure 19, and the second-resolution impurity pattern is shown in figure 20.
Suspending the total amount of the secondary split solid in 400ml of water, heating to 50 ℃, adding acetic acid to dissolve the secondary split solid, adding 10g of calcium acetate and 2g S-methylbenzylamine into the dissolved solution, cooling the dissolved solution to 15 ℃, crystallizing for 6h, separating out a solid, filtering, and washing the solid with water to obtain a tertiary split solid, namely a crude calcium levofolinate product, 38g of the tertiary split solid, wherein the yield is =84%, the isomeric diagram of the crude product is shown in figure 21, and the impurity diagram of the crude product is shown in figure 22.
Suspending the crude calcium levofolinate in 400ml of water, heating to 50 ℃, adding acetic acid to dissolve, adding 1500ml of absolute ethyl alcohol into the dissolved solution to crystallize for 5h, separating out solids, filtering, washing with absolute ethyl alcohol, and drying to obtain 11.2g of the finished calcium levofolinate with yield =90%, wherein the isomeric diagram of the finished product is shown in figure 23, and the impurity diagram of the finished product is shown in figure 24.
The difference from example 1 is that the resolving agent R- (. alpha. -phenylethylamine is replaced by S-methylbenzylamine.
Comparative example 3:
the high-purity levorotatory calcium folinate is prepared by taking a crude calcium folinate product as a raw material, and comprises the following steps:
suspending 51.1g (0.1 m o l) crude calcium folinate and 25g sodium bromide in 400ml water, heating to 50 ℃ to dissolve, cooling the dissolved solution to 15 ℃ to crystallize for 6h, separating out solid, filtering, washing the solid with water, and combining the filtrates.
Adding 10g of calcium acetate and 2g S- (alpha) -phenylethylamine into the filtrate, cooling the solution to 15 ℃, crystallizing for 6h, separating out solid, filtering, and washing the solid with water to obtain 57.5g of primary resolved solid with yield =89%, wherein the primary resolved isomeric pattern is shown in figure 25, and the primary resolved impurity pattern is shown in figure 26.
Suspending the total amount of the first-resolution solid in 400ml of water, heating to 50 ℃, adding acetic acid to dissolve the first-resolution solid, adding 10g of calcium acetate and 2g S- (alpha) -phenylethylamine into the dissolved solution, cooling the dissolved solution to 15 ℃, crystallizing for 6h, separating out the solid, filtering, and washing the solid with water to obtain 47.8g of second-resolution solid, wherein the yield is =88%, the second-resolution isomeric pattern is shown in figure 27, and the second-resolution impurity pattern is shown in figure 28.
Suspending the whole amount of the secondary split solid in 400ml of water, heating to 50 ℃, adding acetic acid to dissolve the secondary split solid, adding 10g of calcium acetate and 2g S- (alpha) -phenylethylamine into the dissolved solution, cooling the dissolved solution to 15 ℃, crystallizing for 6h, separating out the solid, filtering, and washing the solid with water to obtain 40.1g of tertiary split solid-calcium levofolinate crude product, wherein the yield is =86%, the crude product isomeric diagram is shown in an attached figure 29, and the crude product impurity diagram is shown in an attached figure 30.
Suspending the crude calcium levofolinate in 400ml of water, heating to 50 ℃, adding acetic acid to dissolve, adding 1500ml of absolute ethyl alcohol into the dissolved solution to crystallize for 5h, separating out solids, filtering, washing with absolute ethyl alcohol, and drying to obtain 12.2g of the finished calcium levofolinate with yield =91%, wherein the isomeric diagram of the finished product is shown in figure 31, and the impurity diagram of the finished product is shown in figure 32.
The difference from example 1 is that the resolving agent R- (. alpha. -phenylethylamine is replaced by S- (. alpha. -phenylethylamine).
Example 2
The high-purity levorotatory calcium folinate is prepared by taking calcium folinate as a raw material, and comprises the following steps:
suspending 51.1g (0.1 m o l) calcium folinate and 25g sodium bromide in 400ml water, heating to 40-60 deg.C to dissolve, cooling to 0-20 deg.C to crystallize for 5-20 h, precipitating solid, filtering, washing the solid with water, and mixing filtrates.
Adding 8g of calcium formate and 2g R- (. alpha. -phenylethylamine) into the filtrate, cooling the dissolved solution to (0-20) ° C, crystallizing for (5-20) h, precipitating a solid, filtering, and washing the solid with water to obtain 59.5g of a first-time resolved solid, wherein the yield is = 91%.
Suspending the total amount of the first resolved solid in 400ml water, heating to 40-60 deg.C, adding formic acid to dissolve, adding 8g calcium formate and 2g R- (alpha) -phenylethylamine into the dissolved solution, cooling to 0-20 deg.C, crystallizing for 5-20 h, separating out solid, filtering, washing the solid with water to obtain 50g second resolved solid,The yield = 89%.
Suspending the total amount of the secondary split solid in 400ml of water, heating to (40-60) DEG C, adding formic acid to dissolve the secondary split solid, adding 8g of calcium formate and 2g R- (alpha) -phenylethylamine into the dissolved solution, cooling the dissolved solution to (0-20) DEG C, crystallizing for (5-20) h, separating out the solid, filtering, and washing the solid with water to obtain the tertiary split solid, namely 43.8g of crude calcium levofolinate, wherein the yield is = 89.2%.
Suspending the crude calcium levofolinate in 400ml of water, heating to 40-60 deg.C, adding formic acid to dissolve, adding 1500ml of absolute ethanol into the dissolved solution, crystallizing for 2-6 h, separating out solid, filtering, washing with absolute ethanol, and drying to obtain 13.2g of calcium levofolinate, wherein the yield is =91.5%, the chloride is less than or equal to 0.05%, the isomeric pattern of the final product is shown in figure 33, and the impurity pattern of the final product is shown in figure 34.
Example 3
The high-purity levorotatory calcium folinate is prepared by taking calcium folinate as a raw material, and comprises the following steps:
suspending 51.1g (0.1 m o l) calcium folinate and 25g sodium bromide in 400ml water, heating to 40-60 deg.C to dissolve, cooling to 0-20 deg.C to crystallize for 5-20 h, precipitating solid, filtering, washing the solid with water, and mixing filtrates.
Adding 12g of calcium propionate and 2g R- (. alpha. -phenylethylamine) into the filtrate, cooling the solution to (0-20) DEG C, crystallizing for (5-20) h, precipitating a solid, filtering, and washing the solid with water to obtain 60g of a first-time resolved solid, wherein the yield is = 90.5%.
Suspending the total amount of the first resolved solid in 400ml water, heating to 40-60 deg.C, adding propionic acid to dissolve, adding 12g calcium propionate and 2g R- (alpha) -phenylethylamine into the dissolved solution, cooling to 0-20 deg.C, crystallizing for 5-20 h, separating out solid, filtering, and washing with water to obtain second resolved solid 51.5g,Yield = 90.3%.
Suspending the total amount of the secondary split solid in 400ml of water, heating to (40-60) DEG C, adding propionic acid to dissolve the secondary split solid, adding 12g of calcium propionate and 2g R- (alpha) -phenylethylamine into the dissolved solution, cooling the dissolved solution to (0-20) DEG C, crystallizing for (5-20) h, separating out the solid, filtering, and washing the solid with water to obtain the tertiary split solid, namely 44.8g of crude calcium levofolinate, wherein the yield is = 90.2%.
Suspending the crude calcium levofolinate in 400ml of water, heating to 40-60 ℃, adding propionic acid to dissolve, adding 1500ml of absolute ethyl alcohol into the dissolved solution to crystallize for 2-6 h, separating out solids, filtering, washing with absolute ethyl alcohol, and drying to obtain 13.7g of the finished calcium levofolinate, wherein the yield is =92.1%, the chloride is less than or equal to 0.05%, the isomeric diagram of the finished product is shown in figure 35, and the impurity diagram of the finished product is shown in figure 36.
Example 4
From the preparation of tetrahydrofolic acid to the preparation of high-purity calcium levofolinate by NaHSO3 Reducing folic acid to tetrahydrofolic acid, and preparing calcium folinate by using ethyl formate as a formylation reagent. And then the obtained calcium folinate is used as a raw material to prepare the high-purity L-calcium folinate.
Suspending 10g folic acid in 60ml water, adding sodium hydroxide solution, stirring to dissolve, adding 15g sodium bisulfite, standing at 70 deg.C for 1.5 hr, decolorizing, filtering, adding vitamin C into the filtrate, adjusting pH to 4.0, and filtering to obtain solid A. Dissolving the solid A, adding 60ml of methyl formate, reacting for 20 hours, crystallizing, filtering and drying to obtain a solid B. Dissolving the solid B, reacting with calcium chloride, filtering, adding absolute ethyl alcohol into the filtrate, crystallizing, filtering, and drying to obtain a crude calcium folinate product.
The same procedure as in example 3 was repeated to produce high-purity calcium levofolinate from the obtained calcium folinate.
Claims (7)
1. The preparation method of high-purity calcium levofolinate is characterized by comprising the following steps:
s-1, adding calcium folinate and a resolving agent into water, stirring to dissolve the calcium folinate and the resolving agent, and filtering to obtain a filtrate;
s-2, adding organic acid calcium and a resolving agent into the filtrate, crystallizing and filtering to obtain a primary resolved solid;
s-3, filtering and drying the primary split solid to obtain a crude calcium levofolinate product;
s-4, refining the crude product of the calcium levofolinate to obtain a finished product of the calcium levofolinate;
the resolving agent is R- (alpha) -phenylethylamine.
2. The preparation method of high-purity calcium levofolinate as claimed in claim 1, wherein after the primary resolved solid is obtained, acid is added dropwise to the primary resolved solid, and then organic acid calcium and resolving agent are added, crystallized and filtered to obtain a secondary resolved solid; and filtering and drying the secondary split solid to obtain a crude calcium levofolinate product.
3. The method for preparing high-purity calcium levofolinate according to claim 1, wherein the purification method of crude calcium levofolinate in step S-5 comprises the following steps:
s-11, adding the crude calcium levofolinate into purified water, and adjusting the pH value with organic acid to obtain a dissolved solution;
s-12, filtering the dissolved solution, adding absolute ethyl alcohol into the filtrate, filtering, precipitating and drying to obtain the finished calcium levofolinate.
4. The method for preparing high-purity calcium levofolinate according to claim 1, which comprisesCharacterized in that the calcium folinate is prepared from NaHSO3 Reducing folic acid to tetrahydrofolic acid, and preparing calcium folinate by using ethyl formate as a formylation reagent.
5. The method according to claim 2, wherein the acid used is acetic acid.
6. The method for preparing high-purity calcium levofolinate according to claim 1, wherein the crystallization temperature is 0 to 20 ℃ and the crystallization time is 5 to 10 hours in step S-2.
7. The method of claim 6, wherein the crystallization time in steps S-2 and S-3 is 5 to 6 hours.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111042834.5A CN113666931B (en) | 2021-09-07 | 2021-09-07 | Preparation method of high-purity calcium levofolinate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111042834.5A CN113666931B (en) | 2021-09-07 | 2021-09-07 | Preparation method of high-purity calcium levofolinate |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113666931A true CN113666931A (en) | 2021-11-19 |
CN113666931B CN113666931B (en) | 2023-11-03 |
Family
ID=78548572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111042834.5A Active CN113666931B (en) | 2021-09-07 | 2021-09-07 | Preparation method of high-purity calcium levofolinate |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113666931B (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993017022A1 (en) * | 1992-02-20 | 1993-09-02 | Bracco S.P.A. | Process for separating stereoisomers of folinic acid |
WO1995033749A1 (en) * | 1994-06-08 | 1995-12-14 | Bracco S.P.A. | A process for the preparation and separation of diastereomeric salts of folinic acid |
CN1401647A (en) * | 2002-09-13 | 2003-03-12 | 中国科学院上海有机化学研究所 | High specific rotatory power levoleucovorin calcium and resolution method thereof |
CN1456561A (en) * | 2003-04-01 | 2003-11-19 | 杭州华卫制药技术开发有限公司 | Preparations of leucovorin and its carbonates |
CN101407518A (en) * | 2007-10-11 | 2009-04-15 | 南京莱尔生物化工有限公司 | Method for resolving and salifying (6R,S)-5-formyl-tetrahydrofolic acid |
CN105367574A (en) * | 2015-10-27 | 2016-03-02 | 浙江大为药业有限公司 | Process for preparing high purity sinistral leucovorin calcium |
-
2021
- 2021-09-07 CN CN202111042834.5A patent/CN113666931B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993017022A1 (en) * | 1992-02-20 | 1993-09-02 | Bracco S.P.A. | Process for separating stereoisomers of folinic acid |
WO1995033749A1 (en) * | 1994-06-08 | 1995-12-14 | Bracco S.P.A. | A process for the preparation and separation of diastereomeric salts of folinic acid |
CN1401647A (en) * | 2002-09-13 | 2003-03-12 | 中国科学院上海有机化学研究所 | High specific rotatory power levoleucovorin calcium and resolution method thereof |
CN1456561A (en) * | 2003-04-01 | 2003-11-19 | 杭州华卫制药技术开发有限公司 | Preparations of leucovorin and its carbonates |
CN101407518A (en) * | 2007-10-11 | 2009-04-15 | 南京莱尔生物化工有限公司 | Method for resolving and salifying (6R,S)-5-formyl-tetrahydrofolic acid |
CN105367574A (en) * | 2015-10-27 | 2016-03-02 | 浙江大为药业有限公司 | Process for preparing high purity sinistral leucovorin calcium |
Also Published As
Publication number | Publication date |
---|---|
CN113666931B (en) | 2023-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0153696B1 (en) | Process for preparing 5,6,7,8-tetrahydro-6-(l-erythro-1',2'-dihydroxypropyl) pterin | |
EP0191335B1 (en) | Preparation process of (6r)-tetrahydro-l-biopterin | |
HU203237B (en) | Process for producing biological active isomer of tetrahydrofolic acid derivatives by fractional crystallization | |
CN1030079C (en) | Process for preparation of (6S)-and (6R)-tetrahydrofolic acid | |
CN107793418A (en) | Industrial production method of tofacitinib citrate | |
US4649197A (en) | Sulfate of 5,6,7,8-tetrahydro-L-erythro-biopterin and process for preparing the same | |
JP4381684B2 (en) | Method for producing sugar alcohol | |
US20230054325A1 (en) | Compositions comprising folic acid derivatives, their preparations and methods of use | |
IE63929B1 (en) | Method for the preparation of tetrahydrofolates | |
US9090925B2 (en) | Synthesis of (6S)-5,6,7,8-tetrahydrofolic acid | |
CN113666931A (en) | Preparation method of high-purity calcium levofolinate | |
CA2814018C (en) | Preparation process of (6r)-tetrahydrobiopterin hydrochloride | |
CN112142740B (en) | Process for the preparation of imipenem | |
CN110759933A (en) | Preparation method of cefdinir impurity G | |
CN111777636B (en) | Preparation method of medicine for myocardial protection | |
CN115611899B (en) | Preparation method of L-5-methyltetrahydrophthalic acid | |
EP2502625A1 (en) | Process for the preparation of crystalline levofolinic acid | |
CN116063358B (en) | Preparation method of coenzyme II related substances | |
CN114702511B (en) | Preparation method of trans-isomer of ceftibuten | |
EP1200436B1 (en) | Method for making pure stereoisomers of tetrahydrofolic acid ester salts and tetrahydrofolic acid by fractionated crystallisation of tetrahydrofolic acid salts | |
CN117865960A (en) | Method for synthesizing L-5-methyltetrahydrofolate calcium with enantioselectivity | |
CN110872293A (en) | Chemical synthesis and purification method of biopterin | |
CN115161359A (en) | Natural (6S) -5-methyl tetrahydrofolate and preparation method thereof | |
CN117186102A (en) | Preparation method of N2-methylamino-tetrahydrofolic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |